Using gene editing to target and eliminate HIV in T cells
T cell-targeted lentiviral vectors with Cas9/RNP for the in vivo gene therapy of HIV-AIDS
This study is exploring a new way to get rid of HIV from the body using a technique called CRISPR, which targets the T cells that the virus infects, with the hope of finding a lasting solution for people living with HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10749002 on NIH RePORTER |
What this research studies
This research investigates a novel approach to eliminate HIV from the body by using a gene editing technique called CRISPR. The method involves delivering a Cas9 nuclease and guide RNA specifically to T cells, which are the primary cells infected by HIV. By targeting these cells, the goal is to disrupt the virus's ability to replicate and persist in the body. The research utilizes a specially designed lentiviral vector that can effectively deliver the gene editing components to T cells in vivo, potentially leading to a functional cure for HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are currently on antiretroviral therapy and have a suppressed viral load.
Not a fit: Patients who are not infected with HIV or those who have advanced AIDS with significant immune system damage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that eliminates HIV from the body, allowing patients to stop antiretroviral therapy without the risk of viral rebound.
How similar studies have performed: Other research has shown promising results using CRISPR technology for gene editing in various contexts, but this specific application for HIV is still in the experimental phase.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Kumar, Priti — Yale University
- Study coordinator: Kumar, Priti
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.